CTAG2 and ovarian serous adenocarcinoma: In the serous ovarian cancer patients of cohort 2 (n = 20/80), detectable antibodies (Z-scores > 0) were seen against CTAG2 (n = 3/20, 15%), SHARPIN (n = 2/20, 10%), PNMA2 (n = 2/20, 10%), MAGEB4 (n = 1/20, 5%), MRFAP1L1 (n = 1/20, 5%), SERPINB1 (n = 1/20, 5%) and XAGE3 (n = 1/20, 5%).